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dicted combination therapy with ATX, LAS, and A2As. This suggests these medi-
cations may be used differently in clinical practice.
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OBJECTIVES: Bipolar disorder (BD) is associated with a high burden on healthcare
resources. A secondary objective of the Wide AmbispectiVE study of the clinical
management and burden of bipolar disorder (WAVE-bd) was to assess healthcare
resource utilization among BD patients. METHODS: Multinational, multicenter,
non-interventional, cohort study of patients diagnosed with BD-I/BD-II with 1
mood episode in the preceding 12 months (retrospective data collection) followed
by a minimum 9 months’ prospective follow-up. Study population was represen-
tative of BD populations from 8 European and 2 Latin American countries. Multi-
variate analyses determined factors associated with higher incidence of resource
use (number of visits per year), measured by parameter estimates (ParEst [95% CI])
0. RESULTS: Multivariate analyses included 2,896 patients. Factors associated
with a higher incidence of hospitalizations included: psychotic symptoms during
the study index episode (0.08 [0.02; 0.14]); a higher number of previous hospitaliza-
tions (0.04 [0.03; 0.04]); receiving anxiolytics during the study index episode (0.12
[0.06; 0.17]); enrolment in hospital settings (0.13 [0.03; 0.23]). The incidence of emer-
gency room visits was increased in patients with: rapid cycling (0.13 [0.06; 0.19]); a
history of suicide attempts (0.08 [0.02; 0.14]); a higher number of previous hospital-
izations (0.01 [0.01; 0.02]). The incidence of programmed psychiatrist visits was
increased in patients: with rapid cycling (0.90 [0.36; 1.44]); with a higher number of
previous hospitalizations (0.11 [0.06; 0.16]); enrolled in private practices (1.31 [0.07;
2.55]); receiving antipsychotics during study index event (0.81 [0.37; 1.25]). Overall,
clinical factors associated with higher incidence of resource use included: rapid
cycling (2.22 [0.84; 3.61]); co-morbidity of thyroid disease (2.21 [0.49; 3.92]); a higher
number of previous hospitalizations (0.25 [0.12; 0.38]); receiving antipsychotics dur-
ing the study index episode (1.63 [0.50; 2.76]). CONCLUSIONS: Several clinical fac-
tors are associated with higher resource utilization in BD patients. These factors
could aid in identification of high-risk patients.
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OBJECTIVES: Mortality among schizophrenia patients is higher than the general
population. Antipsychotics are the mainstay of schizophrenia treatment but have
been linked to life threatening adverse events. Therefore the objective of the study
was to systematically review available literature examining the risk of mortality
associated with antipsychotic use among schizophrenia patients.METHODS: Sys-
tematic review of English literature was conducted in MEDLINE, PubMed,
PsychInfo, EMBASE, Cochrane databases, and IPA from 1966 to October 2011 using
nine element eligibility criteria to identify studies examining the association be-
tween antipsychotic use and mortality. The primary inclusion criteria involved
diagnosis of schizophrenia, exposure to antipsychotics, at least one year follow up,
and ascertainment ofmortality. Findings from case-control, cohort, and controlled
trial studies were abstracted for evidence table preparation and possible
meta-analyses. RESULTS: Overall sixteen studies were included after employing
nine element eligibility criteria. The studies were heterogeneous in terms of study
designs; follow up period, and control of selection bias and confounding. Conse-
quently meta-analysis was not conducted. Nine out of sixteen studies concluded
increased risk of mortality among antipsychotic users compared to non-users.
Three out of four studies examining the antipsychotic polypharmacy found signif-
icant positive effect onmortality. One out of two studies examining the compliance
with antipsychotics found negative effect on mortality. One out of two studies
examining association of antipsychotic dosages found significant association with
increased mortality. One study ascertained stable association with antipsychotic
treatment intensity and increased cardiovascular mortality while other found no
significant association. The follow up period varied from 1 to 17 years. Prospective
studies controlled for lifestyle related factors while retrospective studies for some
comorbidities and co-medications. CONCLUSIONS: Literature review revealed that
antipsychotic use and antipsychotic polypharmacy increased the risk of mortality.
Well designed observational studies accounting for selection bias and confounding
are needed to establish the relationship.
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OBJECTIVES:To study factors associatedwith risk of dropout amongheroin addicts
enrolled in a community-based methadone maintenance treatment (MMT) clinic
in Solo, Central Java, Indonesia. METHODS: This was an ambi-directional cohort
study. The index date was patients’ first entry identified from medical records.
Patients enrolled from September 2009 were followed up until departure from the
clinic or otherwise censored in May 2011. Other data collected were methadone
doses, risk behaviour, and sociodemographic characteristics. Kaplan-Meier
method was used to estimate retention rate and Cox proportional hazard regres-
sions were used to determine factors associated with dropout from treatment.
RESULTS: Ninety-eight patients aged 31.6 years old on average contributed to
14,804 person-days of folllowup. The retention ratewas 24.2%after 21monthswith
median retention time of 78 days. The median and maximum dose were 43.1 mg
and 150 mg, respectively. Multivariate analysis showed that methadone dose be-
low 80 mg (HR2.4, p0.014, 95% CI1.2-4.8) and absence of family support
(HR5.0, p0.001, 95% CI2.4-10.6) were significantly associated with risk of drop-
out. HIV status, overdose history, criminal record, duration of addiction, distance
from clinic, marital status, and employment were not statistically significant pre-
dictors of dropout. CONCLUSIONS: Despite high prevalence of injecting drug users
(IDUs) in the area, low retention rate of the MMT clinic indicates that the commu-
nity-based programmight have been suboptimally utilised or else poorlymanaged.
Attaining maintenance phase at a minimum dose of 60 mg was insufficient to
ensure compliance. Health workers should maintain relationships with patients’
family to help support and monitor the treatment. Similar studies in hospital or
correctional institution settings and/or other areas are needed to confirm the find-
ings as well as economic analyses to anticipate waste of resources.
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OBJECTIVES: Depressive disorders affect 35 million US adults annually. A large
US health plan offers some members a “Refill and Save Program” (RSP), with dis-
counted copayments for desvenlafaxine (DSV) and extended-release venlafaxine
(VENXR) when refilled within 30 days after previous fill run-out. This study com-
pared adherence between RSP and non-RSP cohorts.METHODS: This retrospective
claims database study examined adult commercial members with 1 claim for
DSV or VENXR fromOctober 1, 2009 – March 31, 2010; the first claim date was index
date. Members with schizophrenia were excluded. Members were continuously
enrolled for 6 months pre-index and 9 months post-index. Proportion of days cov-
ered (PDC) on index antidepressant was modeled with ordinary least-squares re-
gression, controlling for index antidepressant, naïve antidepressant use, demo-
graphic and plan characteristics. Subset analysis was conducted on naïve and
continuing index antidepressant users and on subjects with no change in post-
index RSP exposure. RESULTS: The study population included 46,138 members
withmean age 4812 years and 75.3% female, divided between RSP (n28,925) and
non-RSP (n17,213): 21.4% were naïve to their index antidepressants. Mean PDC
was 69% in RSP, 65% in non-RSP (p0.001). Regression results showed PDC was 6.5
percentage points higher (p0.001) in the RSP versus non-RSP cohort. PDC in RSP
cohort was 8.2 percentage points higher (p0.001) among naïve index antidepres-
sant users, and 6.4 percentage points higher (p0.001) among continuing users.
Analyses on those with no change in post-index RSP exposure yielded similar
significant results but with smaller effect. CONCLUSIONS: The RSP cohort, versus
non-RSP, had higher index antidepressant PDC. These results suggest that copay-
ment discounts may have a positive impact on adherence to desvenlafaxine and
extended-release venlafaxine HCl.
PMH24
DIFFERENCES IN HEALTH CARE UTILIZATION AND ASSOCIATED COSTS
BETWEEN PATIENTS PRESCRIBED VERSUS NOT PRESCRIBED OPIOIDS DURING
AN INPATIENT OR EMERGENCY DEPARTMENT VISIT
Xie L1, Joshi AV2, Harnett J2, Mardekian J2, Schaaf D2, Shah N3, Baser O1
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2Pfizer, Inc., New York,
NY, USA, 3Mayo Clinic, Rochester, MN, USA
OBJECTIVES: Compare health care resource utilization (HCRU) and costs between
patients prescribed opioids versus those who were not during emergency depart-
ment (ED) or inpatient visits. METHODS: Patients with ED/inpatient visits were
selected from the MarketScan Commercial and Medicare Supplemental Database
linked with the Marketscan Hospital Discharge Database (1/12007–9/30/2009). Pa-
tients prescribed opioids in the ED/inpatient setting were assigned to the ‘Opioid
Patient (RxOP)’ cohort. The first prescription date was the index date. Among pa-
tients not prescribed opioids, the ‘Non-Opioid Patient (NoRxOP)’ cohort, a random
date between the first ED/inpatient admission and 30SEPT2009 served as the index
date. Additional inclusion criteria were: age older than 12 years at index date, and
12months of continuous enrollment before and after the index date. Patients with
opioid prescriptions during the pre-index period were excluded. Differences in
patients’ age, gender, geographic region, comorbidities, and HCRU during the pre-
index period were adjusted by 1:1 propensity score (PS) matching (PSM). RESULTS:
Overall, opioids were prescribed in 56% of patients in ED, and 71% in inpatient
setting. After excluding patients with pre-index opioid use (N163), among 27,599
eligible patients, 68% (RxOP: N18,819) were prescribed opioids, and 32% (NoRxOP:
N8,780) were not. The majority of patients (96%, N18,031) were prescribed im-
mediate-release opioids and 4% (N788) extended-release opioids (LAO use
slightly higher in ED versus inpatient, 6.5% versus 3.7%, p0.01). Among the 5099 PS
matched patients, adjusted results showed that RxOP patients had more inpatient
A85V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
(1.58 vs. 0.36, p0.01), physician (10.17 vs.8.96, p0.01) and ED visits (1.12 vs. 0.67,
p0.01) than NoRxOP patients in the follow-up period. RxOP users had twice the
total healthcare costs ($49,766 vs. $19,875, p0.01) than NoRxOp patients.
CONCLUSIONS: A large percentage of patients are prescribed opioids for the first
time during ED/inpatient visits and incur a significantly higher resource use and
economic burden than those who are not.
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OBJECTIVES: Schizophrenia and bipolar disorder (BD) are psychiatric disorders
that are associated with a substantial clinical and economic burden. Hospitaliza-
tion and in-patient care commonly account for a large proportion of medical costs
in these illnesses. A secondary objective of the Italian Burden of Illness on Schizo-
phrenia and BD (IBIS) study is to assess any differences in terms of cost of illness for
patients with schizophrenia and BD switching from QTP-IR to QTP-XR.METHODS:
Multicenter, retrospective, observational, real world cohort study (NCT01392482).
The data shown are interim results collected from administrative databases in 6 of
20 Italian Local Health Units included in the study. Data were collected between 1
January 2009 and 31 December 2010. Patients that switched fromQTP-IR to QTP-XR
were included for analysis. Data were collected 6 months before (IR period) and 6
months after (XR period) the switch. RESULTS: In total, 213 patients switched
medication from QTP-IR to QTP-XR (86 with schizophrenia, 127 with BD). For pa-
tients with schizophrenia, disease-related costs per patient totaled €4123 during
the IR period and €3832 during the XR period, indicating a decrease of 7%. Although
hospitalization costs per patient remained similar after the switch (IR period:
€1111, 26.9% of total costs; XR period: €998, 26.0% of total costs), care/nursing home
costs decreased in the XR period (IR period: €1906, 46.2% of total costs; XR period:
€1330, 34.7% of total costs). For patients with BD, disease-related costs per patient
decreased by 23%, from €3877 during the IR period to €2,973 during the XR period.
Hospitalization costs per patient fell substantially after the switch (IR period: €2659,
68.6% of total costs; XR period: €1,171, 39.4% of total costs). CONCLUSIONS: These
interim results suggest that switching from QTP-IR to QTP-XR decreases direct
health care costs and in-patient resource use.
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OBJECTIVES: To assess the cost-consequences of cardiometabolic effects of lurasi-
done versus other atypical antipsychotics in adults with schizophrenia and com-
pare the results based on published cardiovascular and diabetes risk equations
from the Framingham Heart Study (FHS), the Atherosclerosis Risk in Communities
study (ARIC), and the San Antonio Heart Study (SAHS).METHODS: A discrete event
simulation model was developed to simulate the economic outcomes based on
cardiometabolic parameter changes after 1-year treatment. With a 3-year time
horizon, the model predicted the number of: 1) incident diabetes cases using each
of the risk equations, and 2) cardiovascular events (e.g., coronary heart disease
(CHD), stroke) (CVD) based on updated cardiometabolic values at 1 year, and esti-
mated the costs associated with each event. Data were drawn from comparative
clinical trials of lurasidone for lurasidone, risperidone, and quetiapine, and from
the literature for olanzapine. Cost data in 2011 values were obtained from public
data sources and discounted at 3.5% annually. RESULTS: Compared with olanzap-
ine, risperidone, and quetiapine, lurasidone: 1) avoided 119, 15, and 7 diabetes
cases and saved $1708, $192, and $95 per patient, excluding the costs of antipsy-
chotics and other events, respectively, when using FHS equation; 2) avoided 58, 8,
and 0 diabetes cases and saved $1,036, $114, and $22 when using SAHS equation;
and 3) avoided 52, 7, and 7 diabetes cases and saved $900, $76, and $88 when using
ARIC equation. Incidence of other CVD eventswas low across all drugs in themodel
due to the short time-horizon. Lurasidone saved$9600 per patient in all compar-
isons when costs of other CVD events and antipsychotics were included.
CONCLUSIONS: In this analysis, lurasidone was a cost-saving option compared to
other antipsychotics. Although the magnitude of cost savings with lurasidone dif-
fered based on the risk equation used, cost savings with lurasidone were consis-
tently observed.
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OBJECTIVES: The aim of this study is to assess the health system and patient costs
associated with antidepressant (AD) use considering the presence and persistence
of depression and anxiety. METHODS: The data was retained from a population-
based health survey on 2004 community dwelling older adults aged  65 years
participating in the ESA (Étude sur la Santé des Aînés) study. Depression and anx-
iety were assessed using DSM-IV criteria and measured at 2 time points one year
apart. Medical and non-medical costs were considered. Medication and health
service use and costs were identified from provincial administrative databases.
The excess costs associated with AD use as a function of mental health status was
analysed using generalized linear models with a gamma distribution (log link),
controlling for a number of factors.RESULTS:The prevalence of antidepressant use
reached 15.5%: SSRIs followed by TCAs were the most common. Significantly
higher health care costs (	: $2840, Wald 260.00, df1, p0.0001) were associated
with ADuse. Among antidepressant users, the results did not show any differences
in costs when accounting for dosage, the number of episodes of use and the pres-
ence of antidepressant switches. Among persistent cases of depression and anxi-
ety the use of AD was associated with lower adjusted total costs reaching CDN
$2724 and CDN $2114, respectively. The use of AD can result in cost savings reach-
ing $154.6 million and $118.4 million per 1 000 000 population, for persistent cases
of depression and anxiety. CONCLUSIONS: This study showed important cost sav-
ings associated with AD use in persistent cases of depression and anxiety. Future
studies should focus on further exploring potential cost savings associated with
different classes of AD in the treatment of different clinical profiles of depression
and anxiety and this in the older adult population.
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OBJECTIVES: The objective of this study was to identify the demographic and clin-
ical characteristics of schizophrenia patients who experience high schizophrenia-
related directmedical costs.METHODS: Patientswith a diagnosis for schizophrenic
disorder (ICD-9-CM code 295) and other non-organic psychoses (ICD-9-CM code
298) were identified from the 2005-2008 Medical Expenditure Panel Survey (MEPS),
a national representative annual survey of non-institutionalized US residents.
Schizophrenia-related direct medical costs were calculated for the following utili-
zation categories: inpatient hospitalizations, prescriptionmedications, and outpa-
tient, office-based physician, emergency department, and home healthcare visits.
Based on the distribution of their total costs, patients were classified into high-cost
(expenditures$16,000) and low-cost (expenditures$16,000) groups. Logistic re-
gression was used to determine the likelihood of high-cost group membership
based on patient demographic and clinical characteristics. Generalized Linear
Models (GLM) regression was used to evaluate the relationships between the inde-
pendent variables and costs. RESULTS: There were 317 patients (weighted fre-
quency2.75 million) with schizophrenia-related costs. Based on the logistic re-
gression procedure, it was seen that older patients were less likely to be in the
high-cost group; for each one-year increase in age, patients were 6.4% less likely to
have high costs (odds ratio [OR]0.936). Patients with a spouse were 83.0% less
likely than those without a spouse to be in the high-cost group (OR0.170). The
GLM regression procedure showed that age, race, and region of residence were
significantly associated with costs. On controlling for other factors, with a one year
increase in age, costs decreased by $127 (p0.001), Caucasians spent $3,831
(p0.019) less than African Americans, and patients living in Southern US spent
$3,718 (p0.01) less than those living in the Northeast. CONCLUSIONS: Identifying
the high-risk population may help policy makers allocate resources more effi-
ciently andhealth care providersmanage patientsmore effectively through assign-
ment of high-risk patients to casemanagers and appropriatemonitoring and treat-
ment.
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OBJECTIVES: To estimate the schizophrenia-related direct medical costs using the
attributable and incremental cost approaches.METHODS: Patients with a diagno-
sis for schizophrenic disorder (ICD-9-CM code 295) and other non-organic psycho-
ses (ICD-9-CM code 298) were identified from the 2005-2008 Medical Expenditure
Panel Survey (MEPS), a nationally representative annual dataset of non-institution-
alized US residents. Schizophrenia-related direct medical costs were estimated for
inpatient hospitalizations, prescription medications, and outpatient, office-based
physician, emergency department, and homehealthcare visits, and overall. For the
attributable cost approach, schizophrenia-related costs were identified from each
of theMEPS event files. For the incremental cost approach, the differences between
the costs for patients with and without schizophrenia for each service type were
calculated to yield the schizophrenia-associated incremental costs. RESULTS:We
identified 348 patients with schizophrenia (weighted frequency3.03 million). The
mean schizophrenia-related direct medical cost per patient-year using the attrib-
utable cost approach was $5,538 (SE$570). With the incremental cost approach,
themean cost per patient-year was $12,369 (SE$1,205) for schizophrenia patients
and $3,198 (SE$47) for non-schizophrenia patients. Thus, the incremental cost
associated with schizophrenia was $9171 (SE1207) per patient-year. When demo-
graphic and clinical factors such as age, sex, race, marital status, insurance status,
socioeconomic status, region of residence, perceived health status, mental health
status, number of medical comorbidities, and number of mental health-related
comorbidities were controlled for using ordinary least squares regression, the
mean schizophrenia-related incremental direct medical cost per patient-year was
$5115 (SE$1240). CONCLUSIONS: This study highlights the high financial burden
of schizophrenia. Although the mean cost per patient-year estimated using the
incremental cost approach was higher than that obtained using the attributable
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